Compare Organon & Co. Common Stock (OGN) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while iShares 10 20 Year Treasury Bond ETF trades at $94.08 (market cap $11.48B). The key difference: iShares 10 20 Year Treasury Bond ETF is far larger — about 3.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and iShares 10 20 Year Treasury Bond ETF for 62 Days on average.
| OGN | TLH | |
|---|---|---|
Market Cap | $3.61B | $11.48B |
Volume | 1,808,049 | 3,119,674 |
Sector | Health | Fixed Income |
52-Week High | $13.81 | $105.36 |
52-Week Low | $5.70 | $91.34 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $92.56 with a slight 0.34% daily gain amid a challenging bond market environment. Technical indicators signal a bearish trend with selling pressure outweighing buying signals. Recent trading volume spikes indicate heightened investor interest as Treasury yields reach multi-decade highs, creating volatility for long-duration bond ETFs.
The outlook remains cautious as rising interest rates pressure bond prices, though the ETF provides exposure to US Treasury securities. Key risks include continued Fed tightening and inflation concerns, while potential stabilization in yields could offer support. Institutional activity shows mixed positioning with some funds reducing exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
